Skip to main content

Recombinant Poliovirus for Cancer Immunotherapy.

Publication ,  Journal Article
Gromeier, M; Nair, SK
Published in: Annu Rev Med
January 29, 2018

Mechanisms to elicit antiviral immunity, a natural host response to viral pathogen challenge, are of eminent relevance to cancer immunotherapy. "Oncolytic" viruses, naturally existing or genetically engineered viral agents with cell type-specific propagation in malignant cells, were ostensibly conceived for their tumor cytotoxic properties. Yet, their true therapeutic value may rest in their ability to provoke antiviral signals that engage antitumor immune responses within the immunosuppressive tumor microenvironment. Coopting oncolytic viral agents to instigate antitumor immunity is not an easy feat. In the course of coevolution with their hosts, viruses have acquired sophisticated strategies to block inflammatory signals, intercept innate antiviral interferon responses, and prevent antiviral effector responses, e.g., by interfering with antigen presentation and T cell costimulation. The resulting struggle of host innate inflammatory and antiviral responses versus viral immune evasion and suppression determines the potential for antitumor immunity to occur. Moreover, paradigms of early host:virus interaction established in normal immunocompetent organisms may not hold in the profoundly immunosuppressive tumor microenvironment. In this review, we explain the mechanisms of recombinant nonpathogenic poliovirus, PVSRIPO, which is currently in phase I clinical trials against recurrent glioblastoma. We focus on an unusual host:virus relationship defined by the simple and cytotoxic replication strategy of poliovirus, which generates inflammatory perturbations conducive to tumor antigen-specific immune priming.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Annu Rev Med

DOI

EISSN

1545-326X

Publication Date

January 29, 2018

Volume

69

Start / End Page

289 / 299

Location

United States

Related Subject Headings

  • Rhinovirus
  • Receptors, Virus
  • Poliovirus Vaccine, Oral
  • Poliovirus
  • Oncolytic Virotherapy
  • Neoplasms
  • Neoplasm Recurrence, Local
  • Internal Ribosome Entry Sites
  • Immunotherapy
  • Humans
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Gromeier, M., & Nair, S. K. (2018). Recombinant Poliovirus for Cancer Immunotherapy. Annu Rev Med, 69, 289–299. https://doi.org/10.1146/annurev-med-050715-104655
Gromeier, Matthias, and Smita K. Nair. “Recombinant Poliovirus for Cancer Immunotherapy.Annu Rev Med 69 (January 29, 2018): 289–99. https://doi.org/10.1146/annurev-med-050715-104655.
Gromeier M, Nair SK. Recombinant Poliovirus for Cancer Immunotherapy. Annu Rev Med. 2018 Jan 29;69:289–99.
Gromeier, Matthias, and Smita K. Nair. “Recombinant Poliovirus for Cancer Immunotherapy.Annu Rev Med, vol. 69, Jan. 2018, pp. 289–99. Pubmed, doi:10.1146/annurev-med-050715-104655.
Gromeier M, Nair SK. Recombinant Poliovirus for Cancer Immunotherapy. Annu Rev Med. 2018 Jan 29;69:289–299.

Published In

Annu Rev Med

DOI

EISSN

1545-326X

Publication Date

January 29, 2018

Volume

69

Start / End Page

289 / 299

Location

United States

Related Subject Headings

  • Rhinovirus
  • Receptors, Virus
  • Poliovirus Vaccine, Oral
  • Poliovirus
  • Oncolytic Virotherapy
  • Neoplasms
  • Neoplasm Recurrence, Local
  • Internal Ribosome Entry Sites
  • Immunotherapy
  • Humans